Literature DB >> 173757

Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

S L Shore, C M Black, F M Melewicz, P A Wood, A J Nahmias.   

Abstract

The phenomenon of antibody-dependent cell-mediated cytoxicity (ADCC) has been extended to include target cells acutely infected with herpes simplex type 1 virus (HSV-1) or herpes simplex type 2 virus (HSV-2) in an in vitro system that employs immune human serum and human blood mononuclear cells. The cytotoxic reaction was detectable after 1 hr of incubation and was complete between 4 and 8 hr. The amount of ADCC noted was directly proportional to the logarithm(10) of the effector: target cell ratio (E:T), and ADCC was noted at E:T as low as 1:1. The mononuclear effector cell was present in the blood of both HSV immune and non-immune individuals. The immune serum factor was demonstrated to be an antibody with specificity for HSV membrane antigen(s) and was reactive with target cells infected with either of the two HSV types. The antibody rendered the mononuclear cell cytotoxic by sensitization of the target cell rather than by direct attachment to or "arming" of the mononuclear cell. The physiochemical properties of the antibody as well as its presence in cord blood demonstrated that it is an immunoglobulin on the IgG class.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 173757

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Heterogeneity of human lymphocyte Fc receptors. II. Relationship to antibody-dependent, cell-mediated cytotoxicity.

Authors:  B J Gormus; M Woodson; M E Kaplan
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

2.  Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

3.  Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.

Authors:  B Norrild; S L Shore; A J Nahmias
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

4.  Antibody-dependent cellular protection against herpes simplex virus dissemination as revealed by viral plauqe and infectivity assays.

Authors:  F Shimizu; K Hanaumi; Y Shimizu; K Kumagai
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

5.  Participation of three major glycoprotein antigens of herpes simplex virus type 1 early in the infectious cycle as determined by antibody-dependent cell-mediated cytotoxicity.

Authors:  B Norrild; S L Shore; T L Cromeans; A J Nahmias
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

6.  Reactivation of latent herpes simplex virus infection of the autonomic nervous system by postganglionic neurectomy.

Authors:  R W Price; J Schmitz
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

7.  Antibody dependent cellular cytotoxicity against coronavirus 229E-infected cells.

Authors:  M J Holmes; K A Callow; R A Childs; D A Tyrrell
Journal:  Br J Exp Pathol       Date:  1986-08

8.  Suppression of in vitro growth of virulent and avirulent herpes simplex viruses by cell-mediated immune mechanisms, antibody, and interferon.

Authors:  F Shimizu; J Satoh; M Tada; K Kumagai
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

9.  Generation of virus-specific cytolytic activity in human peripheral lymphocytes after vaccination with vaccinia virus and measles virus.

Authors:  L H Perrin; D Reynolds; R Zinkernagel; M B Oldstone
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

10.  Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation.

Authors:  S B Greenberg; H R Six; S Drake; R B Couch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.